Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery

• Status: Terminated
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study hopes to determine the optimal antifibrinolytic dosing to decrease bleeding and blood transfusion after cardiac surgery without increasing adverse events

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Pennsylvania
• Treatments: Aminocaproic Acid

Criteria

Inclusion Criteria:

• Ability to sign informed consent

• Elective cardiac surgery patients undergoing primary surgery involving circulatory arrest

Exclusion Criteria:

• Inability to sign informed consent

• Baseline hypercoagulable condition as defined in medical record

• Coronary disease with untreated lesions or recent coronary stent placement

• Severe renal dysfunction (ESRD) as documented in medical record